Abstract
Breast cancer is the number one cancer of women in the world. In middle income countries, and in many low income countries, breast cancer has become the most frequent cancer in women, supplanting cancer of the cervix. In such countries, breast cancer is usually diagnosed at an advanced stage, the majority in stage III and IV, indicating substantial delay in diagnosis. Further, because of the age distribution of the population pyramid, the majority of breast cancers are diagnosed in women under the age of 50. However, that age distribution does not mean that breast cancer is a different disease than in the West. Where population-based cancer registry data are available, it becomes clear that the individual risk for women at every age is no greater than in the West, and in many countries much less.
Zusammenfassung
Brustkrebs ist die Krebsart, die bei Frauen weltweit an erster Stelle steht. In Staaten mittleren Wohlstandes und in einigen Staaten geringeren Wohlstandes wurde Brustkrebs bei Frauen zur häufigsten Krebsart und hat somit den Krebs der Zervix verdrängt. In solchen Ländern wird Brustkrebs üblicherweise im fortgeschrittenen Stadium diagnostiziert, hauptsächlich im Stadium III und IV, was zu einer erheblichen Verzögerung der Diagnosestellung führt. Des Weiteren wird aufgrund der Altersverteilung in der Bevölkerungspyramide, die Mehrzahl der Brustkrebserkrankungen bei Frauen unter 50 Jahren diagnostiziert. Wie auch immer, diese Alters-Strukturen bedeuten nicht, dass Brustkrebs eine andere Erkrankung als im Westen ist. Wo Datenaufzeichnungen von Krebserkrankten geführt werden, wird schnell deutlich, dass das individuelle Risiko für Frauen jeden Alters nicht größer ist als im Westen und in vielen Ländern viel geringer.
Key words
Früherkennung - Brustkrebs - aufstrebende Länder
Schlüsselwörter
Early detection - breast cancer - emerging world
References
-
1
Barton M B, Harris R, Fletcher S W.
Does this patient have breast cancer? The screening clinical examination: Should it be done? How?.
JAMA.
1999;
282
1270-1280
-
2 Bassett A A. Physical examination of the breast and breast self-examination. In: Miller AB (ed). Screening for Cancer. Academic Press Inc, Orlando Fla 1985; 271-291
-
3
Boulos S, Gadallah M, Neguib S, Essam E A, Youssef A, Costa A, Mittra I, Miller A B.
Breast screening in the emerging world: High prevalence of breast cancer in Cairo.
The Breast.
2005;
14
340-346
-
4 IARC Handbooks on Cancer Prevention .Weight control and physical activity. Vol. 6. IARC Press, Lyon 2002 a
-
5 IARC Handbooks on Cancer Prevention .Breast cancer screening. Vol. 7. IARC Press, Lyon 2002 b
-
6
Miller A B, To T, Baines C J, Wall C.
Canadian National Breast Screening Study-2.: 13-year results of a randomized trial in women aged 50-59 years.
J Natl Cancer Inst.
2000;
92
1490-1409
-
7
Miller A B, To T, Baines C J, Wall C.
The Canadian National Breast Screening Study-1: Breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years.
Ann Intern Med.
2002;
137
305-312
-
8
Moss S, Waller M, Anderson T J, Cuckle H. (writing committee for the Trial Management Group) .
Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures.
Br J Cancer.
2005;
92
955-960
-
9
Nystrom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist L E.
Long-term effects of mammography screening: updated overview of the Swedish randomised trials.
Lancet.
2002;
359
909-919
-
10
Pisani P, Parkin D M, Ngelangel C. et al .
Outcome of screening by clinical examination of the breast in a trial in the Philippines.
Int J Cancer.
2006;
118
149-154
-
11
Rijnsburger A I, van Oortmarssen G J, Boer R, Draisma G, To T, Miller A B, de Koning H J.
Mammography benefit in the Canadian National Breast Screening Study-2: a model evaluation.
Int J Cancer.
2004;
110
756-762
-
12 Shapiro S, Strax P, Venet L, Venet W. Periodic screening for breast cancer. The Health Insurance Plan Project and its Sequelae, 1963-1986. The Johns Hopkins University Press, Baltimore 1988
1 Based upon a lecture delivered at the first Euro-Arab School of Oncology Meeting, Cairo, Egypt, March 7, 2006
A. B. Miller
Professor Emeritus · Department of Public Health Science · University of Toronto · Canada
Email: ab.miller@sympatico.ca
